Organogenesis Holdings (ORGO) Research & Development (2017 - 2026)

Organogenesis Holdings' Research & Development history runs 10 years deep, the most recent figure standing at $15.2 million for Q1 2026.

• On a quarterly basis, Research & Development rose 42.49% year-over-year to $15.2 million in Q1 2026; TTM through Mar 2026 was $49.1 million, a 2.0% increase from a year earlier, with the FY2025 full-year figure at $44.5 million, down 11.4% from the prior year.
• Research & Development climbed to $15.2 million in Q1 2026 per ORGO's latest filing, from $10.3 million in the prior quarter.
• Across five years, Research & Development topped out at $15.6 million in Q2 2024 and bottomed at $8.6 million in Q1 2022.
• The 5-year median for Research & Development is $10.9 million (2023), against an average of $11.4 million.
• Across the five-year window, Research & Development surged 42.5% in 2024 and sank 33.31% in 2025, its largest moves.
• Year by year, Research & Development stood at $11.4 million in 2022, then rose by 3.29% to $11.8 million in 2023, then slipped by 2.04% to $11.5 million in 2024, then slipped by 10.79% to $10.3 million in 2025, then surged by 47.39% to $15.2 million in 2026.
• Per Business Quant, the three latest ORGO Research & Development figures stand at $15.2 million (Q1 2026), $10.3 million (Q4 2025), and $13.2 million (Q3 2025).